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Abstract: CONTEXT Aldosterone-producing adrenocortical adenomas (APAs) are mainly composed of
clear (lipid rich) and compact (eosinophilic) tumor cells. The detailed association between these histolog-
ical features and somatic mutations (KCNJ5, ATP1A1, ATP2B3 and CACNA1D) in APAs is unknown.
OBJECTIVE To examine the association between histological features and individual genotypes in APAs.
METHODS Examination of 39 APAs subjected to targeted next-generation sequencing (11 KCNJ5, 10
ATP1A1, 10 ATP2B3, and 8 CACNA1D) and quantitative morphological and immunohistochemical
(CYP11B2 and CYP17A1) analyses using digital imaging software. RESULTS KCNJ5- and ATP2B3-
mutated APAs had clear cell dominant features [KCNJ5: clear 59.8% (54.4%-64.6 %) vs. compact 40.2%
(35.4%-45.6 %), P=0.0022; ATP2B3: clear 54.3% (48.2%-62.4 %) vs. compact 45.7% (37.6%-51.8 %),
P=0.0696]. ATP1A1- and CACNA1D-mutated APAs presented with marked intratumoral heterogeneity.
A significantly positive correlation of immunoreactivity was detected between CYP11B2 and CYP17A1 in
tumor cells of KCNJ5-mutated APAs (P=0.0112; ฀=0.7237) , in contrast, significantly inverse correlation
was detected in ATP1A1-mutated APAs (P=0.0025; ฀=-0.8667). CONCLUSION KCNJ5-mutated APAs,
co-expressing CYP11B2 and CYP17A1, were more deviated in terms of zonation-specific differentiation
of adrenocortical cells compared with ATP1A1- and ATP2B3- mutated APAs.
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Context: Aldosterone-producing adrenocortical adenomas (APAs) are mainly composed of clear 
(lipid rich) and compact (eosinophilic) tumor cells. The detailed association between these 
histological features and somatic mutations (KCNJ5, ATP1A1, ATP2B3 and CACNA1D) in APAs is 
unknown. 
Objective: To examine the association between histological features and individual genotypes in 
APAs. 
Methods: Examination of 39 APAs subjected to targeted next-generation sequencing (11 KCNJ5, 10 
ATP1A1, 10 ATP2B3, and 8 CACNA1D) and quantitative morphological and immunohistochemical 
(CYP11B2 and CYP17A1) analyses using digital imaging software.  
Results: KCNJ5- and ATP2B3-mutated APAs had clear cell dominant features [KCNJ5: clear 59.8% 
(54.4%–64.6 %) vs. compact 40.2% (35.4%–45.6 %), P=0.0022; ATP2B3: clear 54.3% (48.2%–62.4 
%) vs. compact 45.7% (37.6%–51.8 %), P=0.0696]. ATP1A1- and CACNA1D-mutated APAs 
presented with marked intratumoral heterogeneity. A significantly positive correlation of 
immunoreactivity was detected between CYP11B2 and CYP17A1 in tumor cells of KCNJ5-mutated 
APAs (P=0.0112; ρ=0.7237) , in contrast, significantly inverse correlation was detected in ATP1A1-
mutated APAs (P=0.0025; ρ=−0.8667).  
Conclusion: KCNJ5-mutated APAs, co-expressing CYP11B2 and CYP17A1, were more deviated in 
terms of zonation-specific differentiation of adrenocortic l cells compared with ATP1A1- and 


















































































































Primary aldosteronism (PA) is one of the most common forms of secondary hypertension, accounting 
for approximately 10% of all hypertensive patients (1-6). Aldosterone-producing adenoma (APA) and 
idiopathic hyperaldosteronism (IHA) are the two major subtypes of PA (1−7). In addition, APAs are 
well known to harbor marked intratumoral heterogeneity in terms of their morphology, genetics and 
steroidogenesis (8-10). Histologically, APAs are mainly composed of two distinctive cell types based 
on their morphological features: “clear cells” and “compact cells” (8, 9). Clear cells are termed as 
“lipid-rich cells” or “zona fasciculata (ZF)-like cells” harboring relatively abundant lipid droplets, 
while “compact cells”, also termed as “lipid-poor cells” or “zona glomerulosa (ZG)-like cells”, are 
small, spherical shaped cells with eosinophilic cytoplasm (8, 9). However, an association between the 
morphological and functional features of these tumor cells has remained virtually unknown. 
In addition, recent studies using next-generation sequencing (NGS) revealed that the great majority 
of APAs harbored somatic mutations of genes encoding ion channels and ion transporters (KCNJ5 
encoding the inwardly rectifying potassium channel subfamily J, member 5; ATP1A1, Na+/K+ ATPase 
1; ATP2B3, Ca2+-ATPase 3 and CACNA1D, voltage-dependent, L-type calcium channel subunit 1D) 
(11-16). These somatic mutations were detected in approximately 90% of all APAs (14, 16, 17). 
Among them, somatic APA mutations in KCNJ5 were the most frequently detected in Caucasian as 
well as Asian patients (11-16) whereas APA mutations in CACNA1D were most frequently detected 
in Afro-American patients (17). 
 Possible genotype-phenotype associations, including histological features of APAs, have been 
proposed especially in APAs carrying KCNJ5 mutations (9, 18, 19). KCNJ5-mutated APAs have a 
clear cell-dominant histology and a relatively large size. In addition, Monticone et al. reported that 
CYP11B2 immunoreactivity was significantly more abundant in ZG-like (n=43) than in ZF-like 
(n=28) APAs and that KCNJ5 somatic mutations were more frequently detected in the latter type (19). 
However, detailed histological features of KCNJ5-mutated APAs and APAs with the less frequently 
detected somatic mutations (ATP1A1, ATP2B3 and CACNA1D) are unknown. In addition, the 
majority of histological studies cited above were performed with manual analyses, which could be 
associated with marked inter- and intra-observer variance (10, 15, 19). We previously proposed that a 
quantitative histological analytical approach using digital imaging software could minimize such 
variance because of high reproducibility in the analysis of KCNJ5-mutated APAs (9). 
Therefore, in this study, we quantitatively analyzed the morphological features and 
immunoreactivity of CYP11B2 and CYP17A1 in combination with targeted NGS for APA 
genotyping. Our objective was to apply state-of-the art and quantifiable technology to establish the 
correlations of histologic features with the distribution of steroidogenic enzymes stratified by 
genotype. 
 
Materials & Methods 
APA cases 
We initially retrieved the cases demonstrating KCNJ5 wild type by initial  sequencing after 
screening in 51 cases from all of the participating institutions (University of Michigan, Ludwig 
Maximilian University of Munich, University of Torino and Yale University) because of the relatively 

















































































































validated the genotypes of those cases (KCNJ5: 11 cases, ATP1A1: 14 cases, ATP2B3: 11 cases, 
CACNA1D: 15 cases). We then exclusively analyzed the 10% formalin fixed and paraffin embedded 
tissue specimens prepared in the good manner without any artifacts examined by histological 
evaluation in hematoxylin and eosin stained tissue slides. We then selected those containing the whole 
area of the tumor at maximum diameter by subsequent histological examination.  The screening above 
yielded the number of the cases examined in this study as follows  (KCNJ5: 11 cases, ATP1A1: 10 
cases, ATP2B3: 10 cases, CACNA1D: 8 cases). 
All the cases examined were clinically diagnosed according to the Endocrine Society Guidelines 
for PA (1). The clinicopathological variables of these cases were summarized in Table 1. All tumors 
were pathologically diagnosed as adrenocortical adenomas according to the criteria of Weiss (20). 
Immunostaining with CYP11B2 antibody was subsequently performed to confirm the 
histopathological diagnosis of APAs (9, 21).  We first screened all available tissue sections (average 
4-5 sections) of all the cases examined and did select the representative tissue section containing the 
largest area of the tumor. The whole tumor areas with maximum dimension, which could reflect 
intratumoral heterogeneity (Fig. 1) were selected among all the available tissue sections of individual 
cases. This study protocol was approved by the Institutional Review Board of each institution.  
 
Quantitative morphological analysis using digital imaging analysis (DIA) 
Hematoxylin and eosin (H&E) staining was performed as reported previously (9). All H&E stained 
sections were digitally scanned and captured using Image Scope AT2 (Leica, Wetzlar, Germany). 
Digital imaging analysis (DIA) was subsequently performed using the software of HALO Area 
Quantification ver. 1.0 (Indica Laboratories, Corrales, NM) to minimize inter-observer variance and 
achieve high reproducibility as reported previously (9). In brief, the whole tumor area was first 
classified into tumor cell and stromal areas based on architectural patterns. We classified tumor cell 
areas into nuclear and cytoplasm areas based on their color spectrums, and cytoplasm areas within a 
tumor cell area further subclassified into clear and compact cells based on the gradients of the 
eosinophilic color spectrum. Two observers analyzed histological parameters in an independent 
manner (Y.O and Y.Y). 
The ratio of each histological component against the whole tumor area was then calculated. The 
percentage of clear and compact cell components within the tumor cell area was also calculated. 
 
Quantitative analysis of CYP11B2 and CYP17A1 immunoreactivity using DIA 
IHC analysis was performed using the antibodies against CYP11B2 (mouse monoclonal) (22) and 
CYP17A1 (rabbit polyclonal) (23) as reported previously (24) All IHC sections were scanned and 
captured as above (9). The modified H-score system was adopted in this study to evaluate 
immunoreactivity of CYP11B2 and CYP17A1 in the quantitative fashion (9, 22, 24). The gradient of 
relative immunointensity was tentatively defined as follows: negative as “0”, weak as “+1”, moderate 
as “+2”, and marked as “+3”. Threshold of score 1+ and 3+ were determined based on the gradient of 
the color spectrum in individual cases and the threshold of score 2+ was set as the midpoint between 
score 1+ and 3+. H-score of the unit area (mm2) was calculated as follows: Σ (Area of the individual 


















































































































Somatic mutation analysis in APAs by next-generation sequencing 
Surgically resected PA adrenals were fixed in 10% neutral-buffered formalin and paraffin embedded 
(formalin fixed paraffin embedded, FFPE) to prepare 5µm serial sections. Tissue samples were 
isolated from six unstained sections by dissecting areas corresponding to serial sections of CYP11B2 
IHC as previously reported (9, 10, 21, 26, 27). Genomic DNA was extracted using AllPrep 
DNA/RNA FFPE kit (QIAGEN) as previously reported. (10, 21, 26, 27). In each case, 20ng of 
isolated gDNA was used to generate a barcoded library by multiplexed PCR using a custom Ion 
AmpliSeq Panel and the Ion AmpliSeq Library kit 2.0 (Life Technologies) according to the 
manufacturer’s instructions. The custom Ion AmpliSeq Panel was designed to target the genes 
previously reported to be mutated in APA or other adrenal diseases (APA_v2 Panel). The APA_v2 
Panel includes 499 independent primer pairs targeting the entire coding regions of genes reported to 
be somatically mutated in APAs (KCNJ5, ATP1A1, ATP2B3 and CACNA1D). Template preparation 
and sequencing of multiplexed templates were performed as previously reported (10, 21, 26, 27) using 
Ion PI Chip on the Ion Torrent Proton sequencer (Life Technologies, Carlsbad, CA). 
 
Statistical analysis 
Multi-comparison analyses were performed for the comparison of histological factors among all 
genotypes of APAs examined (KCNJ5, ATP1A1, ATP2B3 and CACNA1D) using Kruskal-Wallis test. 
The correlation between the proportion of the area of tumor cell subtypes and H-SCORE of CYP11B2 
and CYP17A1 was evaluated using Spearman’s correlation coefficient. P value of <0.05 was 




Comparison of histological features among APAs with different somatic mutations 
The proportions of tumor and stromal areas were not significantly different among APAs with 
different genotypes. The proportion of the nuclear area in ATP1A1-mutated APAs was significantly 
higher than that in ATP2B3-mutated APAs [ATP1A1-mutated: 13.3% (9.3%–16.8 %) vs. ATP2B3-
mutated: 8.8% (6.1%–11.1 %), P=0.0376]. CACNA1D-mutated APAs had a significantly higher 
nuclear/cytoplasm ratio than ATP2B3-mutated APAs [0.20 (0.17–0.26) vs. 0.13 (0.09–0.16), 
P=0.0295] although the proportion of cytoplasm area was not significantly different among the 
different genotypes examined (Table 1, Fig. 2). The proportion of the clear tumor cell component was 
significantly higher than that of the compact one in KCNJ5-mutated APAs [59.8% (54.4%–64.6 %) 
vs. 40.2% (35.4%–45.6%), P=0.0022] but not significantly higher in ATP2B3-mutated APAs [54.3% 
(48.2%–62.4%) vs. 45.7% (37.6%–51.8%), P=0.0696] (Table 1, Fig. 3). Both ATP1A1- and 
CACNA1D-mutated APAs harbored more marked histological intratumoral heterogeneity in terms of 
clear and compact tumor cell distribution, but there was no significant correlation between the 


















































































































Comparison of CYP11B2 and CYP17A1 immunoreactivity among APAs with different somatic 
mutations 
The status of CYP11B2 immunoreactivity (CYP11B2 H score/mm2) was not significantly different 
among ATP1A1-, ATP2B3-, CACNA1D- and KCNJ5-mutated APAs [ATP1A1: 0.53(0.13–0.78), 
ATP2B3: 0.57 (0.41-0.75), CACNA1D: 0.56 (0.10-0.97) and KCNJ5-mutated APA: 0.46 (0.29–0.58)]. 
However, CYP17A1 immunoreactivity (CYP17A1 H score/mm2) was significantly higher in KCNJ5- 
than in ATP2B3-mutated APAs [0.34 (0.26-0.38) vs. 0.13 (0.02-0.22), P=0.0057] and in CACNA1D- 
than in ATP2B3-mutated APAs [0.39 (80.23-0.54) vs. 0.13 (0.02-0.22), P=0.0184] (Table 1, Fig. 3).  
 
Correlation between histological features and immunoreactivity of CYP11B2 and CYP17A1 in 
individual genotypes of APAs 
In KCNJ5-mutated APAs, the status of CYP11B2 immunoreactivity (CYP11B2 H score/mm2) was 
significantly inversely correlated with the proportion of the clear tumor cell component (P=0.00289; 
ρ=−0.6545) but positively with that of compact cells (P=0.00289; ρ=0.6545). There were, however, 
no significant correlations between CYP11B2 immunoreactivity and clear/compact tumor cell 
component in ATP1A1-, ATP2B3- and CACNA1D-mutated APAs as well as between the proportion of 
clear/compact tumor cell component and the status of CYP17A1 immunoreactivity (CYP17A1 H 
score/mm2) in APAs, regardless of their somatic mutations. Of particular interest, CYP11B2 and 
CYP17A1 were significantly positively correlated in KCNJ5-mutated APAs (P=0.0112; ρ=0.7237) 
but inversely in ATP1A1-mutated APAs (P=0.0025; ρ=−0.8667). However, there were no significant 
correlations between CYP11B2 and CYP17A1 immunoreactivity in both ATP2B3- and CACNA1D-
mutated APAs (Fig. 4). 
 
Discussion 
This is the first study demonstrating detailed quantitative morphological characteristics of APAs with 
different somatic mutations identified by targeted next-generation sequencing and including the 
relatively rare ATP1A1, ATP2B3 and CACNA1D somatic mutations.  
 Histological differentiation between clear and compact tumor cells can be occasionally difficult in 
APAs (9). In addition, the previously proposed histological classification of APAs as “ZG” or “ZF” 
did not sufficiently represent the biological or functional features of tumor cells (9). Therefore, in this 
study, we focused on the histological characterization of tumor cells in APAs including those with 
relatively rare somatic mutations (ATP1A1, ATP2B3 and CACNA1D) based on their morphological 
and biological or functional features. 
The results of our present study revealed that clear tumor cells were indeed predominant in 
KCNJ5-mutated APAs but not in ATP1A1-, ATP2B3- and CACNA1D-mutated APAs, all of which 
demonstrated marked intratumoral morphological heterogeneity. These findings were consistent with 
previously reported manual analyses. (16, 19, 28-31). ATP2B3-mutated APAs had relatively smaller 
nuclei than ATP1A1-mutated APAs and lower nuclear to cytoplasm ratios than CACNA1D-mutated 
APAs, indicating that ATP2B3-mutated APAs had smaller nuclei but relatively more abundant 
cytoplasm containing lipid droplets than APAs with other genotypes. Thus, it has become important 

















































































































The status of CYP11B2 immunoreactivity was not significantly different among KCNJ5-, ATP1A1-, 
ATP2B3- and CACNA1D-mutated APAs. These findings did indicate that there were no significant 
differences concerning intratumoral aldosterone biosynthesis among APAs with different somatic 
mutations. However, the status of CYP17A1 immunoreactivity in tumor cells was indeed significantly 
lower in ATP2B3-mutated APAs than in CACNA1D- and KCNJ5-mutated APAs. These findings all 
demonstrated that ATP2B3-mutated APAs could have relatively lower capability of neoplastic 
aberrant cortisol and aldosterone biosynthesis compared to KCNJ5- and CACNA1D -mutated APAs. 
However, further studies including the analysis of co-secretion of cortisol or other glucocorticoids 
possibly demonstrated by the dexamethasone suppression test and of secretion of hybrid steroids such 
as 18-oxocortisol in order to explore the biological significance of the findings above. 
KCNJ5-mutated APAs are larger and more abundant clear cell dominant tumors with a much 
higher frequency of neoplastic aldosterone and cortisol co-secretion than non-KCNJ5-mutated 
genotypes (32-34). In this study, both CYP11B2 and CYP17A in tumor cells of KCNJ5-mutated 
APAs were significantly more abundant than in those of APAs of other genotypes. Hybrid tumor cells 
which co-expressed CYP11B1+/CYP11B2+ and/or CYP17A+/CYP11B2+, and even triple positive 
hybrid cells (CYP17A+/CYP11B1+/CYP11B2+) have been reported in APAs (33, 34). These hybrid 
cells were also reported to be specific for APAs, as they were not detected in normal or hyperplastic 
aldosterone producing cortical cells (31, 33). Tezuka et al., also recently reported that these hybrid 
cells were significantly more abundant and synthesized increased amounts of hybrid steroids such as 
18-oxocortisol in KCNJ5-mutated APAs compared with non KCNJ5-mutated APAs (34). These 
finding also indicated that KCNJ5-mutated APAs could represent more deviated features from 
zonation-based differentiation of normal adrenocortical cells. 
 ATP2B3-mutated APAs demonstrated relative clear cell dominant histology but CYP11B2 and 
CYP17A in tumor cells did not necessarily show a positive correlation. ATP1A1-mutated APAs had 
more compact or eosinophilic tumor cells than other genotypes despite a more pronounced 
intratumoral morphological heterogeneity. Of particular interest, CYP11B2 and CYP17A in tumor 
cells showed an inverse correlation in ATP1A1-mutated APAs. These findings all indicated that 
ATP1A1- and ATP2B3-mutated APAs displayed a more zonation-based or organized differentiation 
than KCNJ5-mutated APAs. In addition, aldosterone biosynthesis in these tumors was more similar to 
that in normal or hyperplastic zona glomerulosa. There were no significant correlations in CACNA1D-
mutated APAs in contrast to KCNJ5-, ATP1A1- and ATP2B3-mutated APAs. Therefore, further 
investigations are required to clarify the mechanistic aspects of the correlation between individual 
somatic mutations and the phenotypes revealed by our present study to achieve a better understanding 
of neoplastic aldosterone overproduction in APAs. 
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Fig. 1. Representative microphotographs of ATP1A1-, ATP2B3-, CACNA1D- and KCNJ5-mutated 
APA tissue sections stained with hematoxylin and eosin (H&E), and immunostained using antibodies 
against CYP11B2 and CYP17A1  
 
Fig. 2. Comparison of histological features of ATP1A1-, ATP2B3-, CACNA1D- and KCNJ5-mutated 
APAs (A-G). The proportion of nuclear area was significantly higher in ATP1A1-mutated APAs than 
in ATP2B3-mutated APAs. [ATP1A1: 13.3% (9.3%–16.8%) versus ATP2B3: 8.8% (6.1%–12.0%), 
P<0.05]. The nuclear to cytoplasm ratio was significantly higher in CACNA1D-mutated APAs than in 
ATP2B3-mutated APAs [0.20 (0.17–0.26) versus 0.13 (0.09– 0.16); P<0.05].  
 
Fig. 3. Comparison of clear and compact tumor cell ratios in ATP1A1-, ATP2B3-, CACNA1D- and 
KCNJ5-mutated APAs (A-D). The ratio of the clear cell component tended to be more abundant than 
the compact cell component in ATP2B3-mutated APAs [54.3% (48.2%–62.4%); versus 45.7% 
(37.6%–51.8%); P=0.0696]. In KCNJ5-mutated APAs, the clear cell component was significantly 
much higher than the compact cell component [59.8% (54.4%–64.6%) versus 40.2% (35.4%–45.6%); 
P=0.0022]. Comparison of the H-score of CYP11B2 and CYP17A1 among ATP1A1-, ATP2B3-, 
CACNA1D- and KCNJ5-mutated APAs (E, F). The status of CYP17A immunoreactivity was 
significant different between KCNJ5 and ATP2B3 (P=0.0057), as well as between ATP2B3- and 
CACNA1D-mutated APAs (P=0.0184).  
 
Fig. 4. Correlation between histological components and steroidogenic enzymes in ATP1A1- (A-E), 
ATP2B3- (F-J), CACNA1D- (K-O) and KCNJ5- (P-T) mutated APAs. Correlation between CYP11B2 
immunoreactivity and proportion of clear cell area (A, F, K and P). Correlation between CYP11B2 
immunoreactivity and proportion of compact cell area (B, G, L and Q). Correlation between the 
proportion of clear cell area and CYP17A1 immunoreactivity (C, H, M and R). Correlation between 
the proportions of compact cell area and CYP17A1 immunoreactivity (D, I, N and S). Correlation 
between the immunoreactivity of CYP11B2 and CYP17A1 (E, J, O and T). E, Both CYP11B2 and 
CYP17A1 showed a significant inverse correlation in ATP1A1-mutated APAs (P=0.0025; 
ρ=−0.8667). P, CYP11B2 immunoreactivity also showed a significant inverse correlation with the 
proportion of clear cell area in KCNJ5-mutated APAs (P=0.0289; ρ=−0.6545). Q, CYP11B2 
immunoreactivity showed a significant correlation with the proportion of compact cell area in KCNJ5-
mutated APAs (P=0.0289; ρ=0.6545). T, Both CYP11B2 and CYP17A1 showed a significant 
















































































































© Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. jc.2019-40189. See 
endocrine.org/publications for Accepted Manuscript disclaimer and additional information. 
Mean±SEM [25-75th percentile] ATP1A1 ATP2B3 CACNA1D KCNJ5 
N 10 10 8 11 
Gender (Male/Female) 9/1 8/2 5/3 3/8 
Age at adrenalectomy (years) 50.8±2.7 [41.5-58.5] 54.9±2.6 [52.0-62.0] 47.5±2.0 [42.3-53.5] 42.2±2.8 [35.0-48.0] 
Baseline systolic blood pressure (mmHg) 158.4±6.7 [140.5-172.3] 166.2±5.4 [150.0-178.0] 146. 9±5.8 [135.0-154.5] 140.8±7.2 [125.0-153.0] 
Baseline diastolic blood pressure (mmHg) 90.2±4.1 [84.0-97.5] 94.6±2.7 [90.0-100.0] 92.8±4.3 [85.5-100.0] 82.6±5.0 [72.0-100.0] 
Maximal tumor Size (mm) 13.4±1.5 [9.0-15.3] 16.3±1.4 [14.0-19.0] 11.4±1.2 [8.3-14.5] 20.7±1.5 [15.0-24.0] 
Nadir serum K+ (mmol/L) 2.8±0.14 [2.5-3.2] 2.7±0.1 [2.4-3.1] 3.1±0.1 [2.6-3.5] 3.4±0.2 [2.9-3.5] 
Baseline plasma aldosterone concentration (PAC) (ng/dL) 46.8±9.7 [12.4-74.1] 79.8±21.0 [27.5-162.2] 49.0±14.5 [17.4-60.6] 37.1±5.8 [24.7-47.0] 
Baseline active renin concentration (ARC) (mU/L) 4.6±1.6 [1.2-9.1] 7.5±4.7 [0.8-9.0] 8.2±1.6 [5.1-12.2] n.d. 
Baseline plasma renin activity (PRA) (ng/ml/hr) 0.8±0.1 [0.6-1.0] 0.6±0.4 [0.15-1.4] 0.3±0.1 [0.1-0.5] 0.2±0.1 [0.1-0.2] 
Baseline PAC/ARC ratio (ng/mU) 158.7±78.5 [40.5-175.8] 411.9±116.7 [127.0-682.0] 60.1±22.5 [16.7-114.3] n.d. 
Baseline PAC/PRA ratio (ng/dL/ng/ml/hr) 68.6±16.0 [33.4-101.6] 152.0±65.6 [40.4-285.0] 188.4±67.0 [58.4-317.5] 270.1±64.8 [133.0-333.0] 
PAC post 240 min. saline infusion test (ng/dL) 26.2±10.8 [10.5-25.7] 43.1±19.8 [11.5-57.7] 22.5±4.5 [11.5-24.7] 30.8±10.8 [18.0-52.3] 
Tumor cell area (%) 80.4±2.9 [71.7-89.3] 74.8±2.7 [67.2-80.1] 70.9±3.1 [60.9-77.8] 73.5±4.0 [67.9-84.4] 
Stroma area (%) 19.6±2.9 [10.7-28.3] 25.2±2.7 [20.0-32.9] 29.1±3.1 [22.2-39.1] 26.5±4.0 [15.7-32.2] 
Nuclear area (%) 13.3±1.7 [9.3-16.8] 8.8±0.8 [6.1-11.1] 11.6±1.4 [9.9-13.6] 10.0±1.2 [6.7-12.6] 
Cytoplasm area (%) 67.2±3.8 [58.8-77.9] 66.0±2.2 [59.8-70.8] 59.3±3.0 [49.6-65.4] 63.5±3.5 [60.3-69.8] 
Nuclear/Cytoplasm ratio 0.21±0.03 [0.15-0.29] 0.13±0.01 [0.09-0.16] 0.20±0.02 [0.17-0.26] 0.16±0.02 [0.11-0.21] 

















































































































Compact 34.2±5.5 [21.0-40.9] 30.4±3.1 [23.1-33.7] 31.9±3.7 [26.7-40.5] 25.5±2.5 [18.5-28.8] 
Clear/Cytoplasm 50.3±6.0 [39.0-67.4] 54.3±3.4 [48.2-62.4] 45.1±6.8 [30.2-58.9] 59.8±3.1 [54.4-64.6] 
Compact/Cytoplasm 49.7±6.0 [32.6-61.0] 45.7±3.4 [37.6-51.8] 54.9±6.8 [41.2-69.8] 40.2±3.1 [35.4-45.6] 
CYP11B2 positive area (%) 34.2±5.9 [12.9-52.6] 44.7±4.4 [39.0-55.2] 34.4±6.7 [10.4-53.9] 35.5±3.7 [25.9-47.1] 
CYP11B2 H-score 0.53±0.12 [0.13-0.78] 0.57±0.08 [0.41-0.75] 0.56±0.13 [0.1-0.97] 0.46±0.06 [0.29-0.58] 
CYP17A1 positive area (%) 25.4±6.6 [3.4-42.1] 11.8±4.2 [2.4-18.0] 32.5±6.0 [21.7-45.1] 32.2±3.2 [25.4-37.4] 
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 Table. Clinicopathological characteristics of aldosterone-producing adenoma (APA) 
cases with ATP1A1, ATP2B3, CACNA1D and KCNJ5 mutation examined in this study. 
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